{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:56:30Z","timestamp":1775091390121,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Accurate measurement of any constructs in clinical studies is of critical importance, especially if the adoption of an intervention relies on detecting a significant treatment effect where one exists. Under Neutral theory, the amount of relevant and irrelevant indicators selected to operationalise the construct contribute equally to the accuracy of the observation. The Neutral or accurate observation is achieved by observing all relevant indicators only. Generic QoL instruments such as EQ-5D are increasingly being accepted as imprecise, especially in rare diseases, based on the relevance of their indicators. QoL is a construct that embodies a patient's subjectivity, individuality, and local circumstances at measurement. SEIQoL-DW is an instrument designed to respect these characteristics of QoL through eliciting indicators or cues directly from the subject along with the proportion of the overall QoL they contribute. EQ-5D and SEIQoL can therefore be considered as being at opposing ends of accuracy in QoL measurement. XLH is a hereditary, progressive, rare disease characterised by phosphate wasting, affecting both children and adults and impacting their QoL. The purpose of this study was to observe if any change in QoL of adult XLH patients were detectable using EQ-5D, SEIQoL eliciting new cues at each visit, and SEIQoL administering baseline cues overall visits (thereby silencing its time-dependency) versus baseline over 12\u00a0months. In addition, any association between the three sets of observations was explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All quality of life scores were observed to decrease from baseline by 13.36%, 7.32% and 2.7% based on SEIQoL\n                      <jats:sub>visit_cues<\/jats:sub>\n                      , SEIQoL\n                      <jats:sub>baseline_cues<\/jats:sub>\n                      , and EQ-5D assessments, respectively. The decrease in the quality of life scores was only statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037) for SEIQoL\n                      <jats:sub>visit_cues<\/jats:sub>\n                      . Beyond the baseline visit, the only highly positive and statistically significant pairwise association was between SEIQoL\n                      <jats:sub>visit_cues<\/jats:sub>\n                      and SEIQoL\n                      <jats:sub>baseline_cues<\/jats:sub>\n                      at M6 (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.782,\n                      <jats:italic>P<\/jats:italic>\n                      value\u2009&lt;\u20090.05) and M9 (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.879,\n                      <jats:italic>P<\/jats:italic>\n                      value\u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      EQ-5D and SEIQoL\n                      <jats:sub>baseline_cues<\/jats:sub>\n                      failed to detect the same statistically significant decrease in QoL observed by SEIQoL\n                      <jats:sub>visit_cues<\/jats:sub>\n                      . Both sets of SEIQoL observations were more closely associated with each other than with EQ-5D. Observing constructs such as QoL in rare diseases benefit from a Neutrality in indicator selection and respecting variation in dominance of various indicators over time.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02250-8","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T08:03:20Z","timestamp":1645603400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Concordance between the schedule for the evaluation of individual quality of life-direct weighting (SEIQoL-DW) and the EuroQoL-5D (EQ-5D) measures of quality of life outcomes in adults with X-linked hypophosphatemia"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-7476","authenticated-orcid":false,"given":"Ravi","family":"Jandhyala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"issue":"3","key":"2250_CR1","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","volume":"105","author":"S Hawley","year":"2019","unstructured":"Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis. J Clin Endocrinol Metab. 2019;105(3):e871\u20138. https:\/\/doi.org\/10.1210\/clinem\/dgz203.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2250_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):1\u201325.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2250_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325\u201333. https:\/\/doi.org\/10.1530\/EJE-15-0661.","journal-title":"Eur J Endocrinol"},{"key":"2250_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"S Lo","year":"2020","unstructured":"Lo S, Lachmann R, Williams A, Piglowska N, Lloyd A. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res. 2020;29:1883\u201393.","journal-title":"Qual Life Res"},{"issue":"1","key":"2250_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"R Padidela","year":"2020","unstructured":"Padidela R, Nilsson O, Makitie O, Beck-Nielsen S, Ariceta G, Schnabel D, et al. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare Dis. 2020;15(1):1\u201311.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2250_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10074","volume":"3","author":"HI Cheong","year":"2019","unstructured":"Cheong HI, Yoo HW, Adachi M, Tanaka H, Fujiwara I, Hasegawa Y, et al. First-in-Asian phase I study of the anti-fibroblast growth factor 23 monoclonal antibody, burosumab: safety and pharmacodynamics in adults with X-linked hypophosphatemia. JBMR Plus. 2019;3(2): e10074. https:\/\/doi.org\/10.1002\/jbm4.10074.","journal-title":"JBMR Plus"},{"key":"2250_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154049","volume":"103S","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Brandi ML, Linglart A, Kamenicky P. Management of X-linked hypophosphatemia in adults. Metabolism. 2020;103S: 154049. https:\/\/doi.org\/10.1016\/j.metabol.2019.154049.","journal-title":"Metabolism"},{"issue":"7","key":"2250_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321\u201334.","journal-title":"J Endocr Soc"},{"key":"2250_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/03007995.2021.1927689","volume":"37","author":"R Jandhyala","year":"2021","unstructured":"Jandhyala R. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs). Curr Med Res Opin. 2021;37:1249\u201357. https:\/\/doi.org\/10.1080\/03007995.2021.1927689.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"2250_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","volume":"11","author":"L Forestier-Zhang","year":"2016","unstructured":"Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, et al. Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis. 2016;11(1):160. https:\/\/doi.org\/10.1186\/s13023-016-0538-4.","journal-title":"Orphanet J Rare Dis"},{"key":"2250_CR11","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1080\/03007995.2021.1947218","volume":"37","author":"R Jandhyala","year":"2021","unstructured":"Jandhyala R. A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch. Curr Med Res Opin. 2021;37:1645\u201355. https:\/\/doi.org\/10.1080\/03007995.2021.1947218.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2250_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12874-021-01279-w","volume":"21","author":"R Jandhyala","year":"2021","unstructured":"Jandhyala R. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC Med Res Methodol. 2021;21(1):86. https:\/\/doi.org\/10.1186\/s12874-021-01279-w.","journal-title":"BMC Med Res Methodol."},{"issue":"7297","key":"2250_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/bmj.322.7297.1297","volume":"322","author":"IJ Higginson","year":"2001","unstructured":"Higginson IJ, Carr AJ. Using quality of life measures in the clinical setting. BMJ. 2001;322(7297):1297\u2013300.","journal-title":"BMJ"},{"issue":"9","key":"2250_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2165\/00002512-200623090-00001","volume":"23","author":"CH Dowding","year":"2006","unstructured":"Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson\u2019s disease. Drugs Aging. 2006;23(9):693\u2013721. https:\/\/doi.org\/10.2165\/00002512-200623090-00001.","journal-title":"Drugs Aging"},{"key":"2250_CR15","doi-asserted-by":"publisher","unstructured":"Jandhyala R. Neutral theory: a conceptual framework for construct measurement in clinical research. (Pre-print) 2020. https:\/\/doi.org\/10.13140\/RG.2.2.33212.16008.","DOI":"10.13140\/RG.2.2.33212.16008"},{"issue":"7298","key":"2250_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/bmj.322.7298.1357","volume":"322","author":"AJ Carr","year":"2001","unstructured":"Carr AJ, Higginson IJ. Are quality of life measures patient centred? BMJ. 2001;322(7298):1357\u201360.","journal-title":"BMJ"},{"issue":"2","key":"2250_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cpr.2008.12.003","volume":"29","author":"SN Haynes","year":"2009","unstructured":"Haynes SN, Mumma GH, Pinson C. Idiographic assessment: conceptual and psychometric foundations of individualized behavioral assessment. Clin Psychol Rev. 2009;29(2):179\u201391.","journal-title":"Clin Psychol Rev"},{"issue":"10","key":"2250_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/0277-9536(95)00116-O","volume":"41","author":"S Ebrahim","year":"1995","unstructured":"Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med. 1995;41(10):1383\u201394.","journal-title":"Soc Sci Med"},{"key":"2250_CR19","unstructured":"O'Boyle C, McGee H, Hickey A, Joyce C, Browne J, O'Malley K, et al. The schedule for the evaluation of individual quality of life (SEIQoL). Administration Manual. 1993."},{"issue":"3","key":"2250_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/00207411.1994.11449285","volume":"23","author":"CA O\u2019Boyle","year":"1994","unstructured":"O\u2019Boyle CA. The schedule for the evaluation of individual quality of life (SEIQoL). Int J Ment Health. 1994;23(3):3\u201323.","journal-title":"Int J Ment Health"},{"key":"2250_CR21","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1007\/978-94-007-0753-5_2623","volume-title":"Encyclopedia of quality of life and well-being research","author":"A Hickey","year":"2014","unstructured":"Hickey A, Burke H. SEIQoL. In: Michalos AC, editor. Encyclopedia of quality of life and well-being research. Dordrecht: Springer; 2014. p. 5739\u201342."},{"issue":"2","key":"2250_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5582\/irdr.2016.01017","volume":"5","author":"M-C Rousseau","year":"2016","unstructured":"Rousseau M-C, Baumstarck K, de Villemeur TB, Auquier P. Evaluation of quality of life in individuals with severe chronic motor disability: A major challenge. Intractable Rare Diseases Research. 2016;5(2):83\u20139. https:\/\/doi.org\/10.5582\/irdr.2016.01017.","journal-title":"Intractable Rare Diseases Research"},{"key":"2250_CR23","unstructured":"Kind P, Brooks R, Rabin R, editors. EQ-5D concepts and method. A collection of papers representing the collective intellectual enterprise of the EuroQol Group, 2005."},{"issue":"3","key":"2250_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1017\/S0033291700022388","volume":"21","author":"HM McGee","year":"1991","unstructured":"McGee HM, O\u2019Boyle CA, Hickey A, O\u2019Malley K, Joyce C. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med. 1991;21(3):749\u201359.","journal-title":"Psychol Med"},{"issue":"7","key":"2250_CR25","doi-asserted-by":"publisher","first-page":"A573","DOI":"10.1016\/j.jval.2014.08.1925","volume":"17","author":"O Ovcinnikova","year":"2014","unstructured":"Ovcinnikova O, Firth Z, Dimova M. An analysis of the health technology assessment recommendation and guidance on use of Eq-5d-5l in cost-effectiveness modeling. Value in Health. 2014;17(7):A573\u20134.","journal-title":"Value in Health"},{"key":"2250_CR26","unstructured":"Ultragenyx Pharmaceutical Inc.: What is X-linked hypophosphatemia (XLH)? (2021). Accessed 16\u201306 2021."},{"issue":"1","key":"2250_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7525-11-3","volume":"11","author":"C Brettschneider","year":"2013","unstructured":"Brettschneider C, K\u00f6nig H-H, Herzog W, Kaufmann C, Schaefert R, Konnopka A. Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with somatoform disorders. Health Qual Life Outcomes. 2013;11(1):3. https:\/\/doi.org\/10.1186\/1477-7525-11-3.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2250_CR28","doi-asserted-by":"crossref","first-page":"230949901877492","DOI":"10.1177\/2309499018774922","volume":"26","author":"J Evans","year":"2018","unstructured":"Evans J, Dattani R, Ramasamy V, Patel V. Responsiveness of the EQ-5D-3L in elective shoulder surgery: does it adequately represent patient experience? J Orthop Surg. 2018;26(2):2309499018774922.","journal-title":"J Orthop Surg"},{"issue":"2","key":"2250_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.17294\/2330-0698.1727","volume":"7","author":"M Hughes","year":"2020","unstructured":"Hughes M, Macica C, Meriano C, Doyle M. Giving credence to the experience of X-linked hypophosphatemia in adulthood: an interprofessional mixed-methods study. J Patient Cent Res Rev. 2020;7(2):176\u201388. https:\/\/doi.org\/10.17294\/2330-0698.1727.","journal-title":"J Patient Cent Res Rev"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02250-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02250-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02250-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T20:03:24Z","timestamp":1645646604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02250-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02250-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-806086\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was granted by Yorkshire and the Humber\u2014Leeds East Research Ethics Committee REC reference: 19\/YH\/0205; IRAS project ID: 262281. All study participants provided informed consent, prior to commencing all study activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author is the Founder and CEO of Medialis Ltd, a medical affairs consultancy and contract research organisation involved in designing and delivering real-world evidence studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}